Endocrine Abstracts

Background: Acromegaly is characterized by hormonal excess of GH and IGF-1, however many patients suffer from hypopituitarism as a result from either disease or treatment. Quality of Life (QoL) is known to be reduced both in acromegaly, with mixed results on the role of biochemical control herein, and hypopituitarism. Studies report the level of surgery-induced hypopituitarism after acromegaly at 12.79% (CI 9.88–16.00%). Treatment of acromegaly aimed at normalization of h...

Somatostatin analogues (SSA) are the mainstay of pituitary-targeted pharmacological treatment in acromegaly, but are characterized by high incidence of resistance in half of cases. The successful management of acromegaly involves in addition to targeting biochemical control the treatment of the metabolic comorbidities and hypopituitarism. In this study we analysed the impact of the concomitant antidiabetic treatment and hormone replacement on the response to SSA. Data were col...